Peyman Pahlavan, MD
Family Medicine · Melrose Park, ILNPI 1063450757
Payments from drug & device makers
Across 449 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AbbVie$1K
- Johnson & Johnson$743
- Bayer$713
- plus $4K from 31 others
What the payments were for
- Food & beverage$12,49499%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,524 |
| Novo Nordisk | 82 | $1,786 |
| Lilly USA, LLC | 56 | $1,530 |
| AbbVie(2 entities) | 49 | $1,382 |
| Johnson & Johnson | 23 | $743 |
| Bayer | 22 | $713 |
| Medtronic | 6 | $535 |
| GSK | 20 | $523 |
| Mylan Specialty L.p. | 21 | $508 |
| Phathom Pharmaceuticals, Inc. | 5 | $380 |
| Merck | 24 | $330 |
| Baxter Healthcare | 2 | $221 |
| Pfizer | 11 | $219 |
| Abbott | 5 | $159 |
| Boston Scientific | 2 | $158 |
| Boehringer Ingelheim | 8 | $148 |
| Aroa Biosurgery Incorporated | 1 | $140 |
| Exact Sciences | 4 | $92 |
| Xeris Pharmaceuticals, Inc. | 3 | $72 |
| Amarin Pharma, Inc. | 3 | $57 |
| Amgen(2 entities) | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Renalytix AI, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Kaleo, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Exeltis, USA Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sonicision$368
- XARELTO$368
- MOUNJARO$365
- FARXIGA$363
- VOQUEZNA$354
- FASENRA$349
- BREZTRI$250
- AIRSUPRA$246
- Kerendia$246
- VRAYLAR$243
- PERI-STRIPS DRY$221
- SpyGlass Discover$133
- RYBELSUS$125
- Ozempic$125
- Signia$115
How this compares
$12,591 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 133 | $138,965 |
| JardianceEmpagliflozin | 109 | $91,909 |
| MounjaroTirzepatide | 78 | $84,704 |
| OzempicSemaglutide | 50 | $75,126 |
| TrulicityDulaglutide | 50 | $51,375 |
| RybelsusSemaglutide | 32 | $50,961 |
| VraylarCariprazine Hcl | 26 | $36,805 |
| XareltoRivaroxaban | 40 | $29,771 |
| LinzessLinaclotide | 41 | $27,815 |
| EliquisApixaban | 31 | $25,313 |
| VascepaIcosapent Ethyl | 49 | $21,600 |
| JanuviaSitagliptin Phosphate | 20 | $17,251 |
| KerendiaFinerenone | 16 | $15,481 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $11,755 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,524 | $153,645168 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,530 | $136,079128 claims |
| Novo NordiskOzempic, Rybelsus | $1,786 | $126,08682 claims |
| Boehringer IngelheimJardiance | $148 | $91,909109 claims |
| AbbVieVraylar, Linzess | $1,382 | $64,62167 claims |
| Johnson & JohnsonXarelto | $743 | $29,77140 claims |
| PfizerEliquis | $219 | $25,31331 claims |
| MerckJanuvia | $330 | $17,25120 claims |
| BayerKerendia | $713 | $15,48116 claims |
| GSKBreo Ellipta, Shingrix, Twinrix | $523 | $12,59752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Melrose Park
- Beth Davis PhillpottsMelrose Park$542K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.